Skip to content
BiologicalX

Comparison

Alpha-Lipoic Acid vs Armodafinil

Side-by-side of Alpha-Lipoic Acid and Armodafinil. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Alpha-Lipoic Acid

  • Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
  • Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
  • R-ALA enantiomer absorbs 40-100% better than racemic mixtures
  • Activates AMPK; produces small HbA1c reductions in T2DM
  • Plasma half-life ~30 minutes; split dosing or sustained-release is standard
  • Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required

Armodafinil

  • FDA approved in 2007 for narcolepsy, shift-work sleep disorder, and OSA residual sleepiness
  • R-enantiomer of modafinil; 150 mg armodafinil is roughly equivalent to 200 mg modafinil
  • Schedule IV controlled in the US; prescription-only globally
  • Longer terminal half-life of about 15 hours produces extended late-day wakefulness coverage
  • Same CYP3A4 induction as modafinil; reduces hormonal contraceptive efficacy
  • Side-effect profile and dermatologic risk warnings mirror modafinil

Side-by-side

Attribute Alpha-Lipoic Acid Armodafinil
Category supplement pharmaceutical
Also known as ALA, thioctic acid, R-ALA, R-lipoic acid Nuvigil, R-modafinil, (R)-(-)-modafinil
Half-life (hr) 0.5 15
Typical dose (mg) 600 150
Dosing frequency 1 to 3 times daily on empty stomach daily, morning
Routes oral, iv oral
Onset (hr) 0.5 1
Peak (hr) 1 3
Molecular weight 206.33 273.35
Molecular formula C8H14O2S2 C15H15NO2S
Mechanism Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake systems; R-enantiomer of modafinil with longer half-life.
Legal status Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany Schedule IV (US); prescription-only globally; not a supplement
WADA status allowed banned
DEA / Rx Not scheduled Schedule IV
Pregnancy Insufficient data; precautionary avoidance Not recommended
CAS 62-46-4 112111-43-0
PubChem CID 864 9148206
Wikidata Q161227 Q4791953

Safety profile

Alpha-Lipoic Acid

Common side effects

  • nausea
  • abdominal discomfort
  • diarrhea
  • sulfurous odor
  • rash (rare)

Contraindications

  • pregnancy and lactation (insufficient safety data)
  • active insulin autoimmune syndrome predisposition

Interactions

  • insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
  • thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
  • biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
  • iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
  • chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)

Armodafinil

Common side effects

  • headache
  • nausea
  • dizziness
  • anxiety
  • insomnia (with later-day dosing)
  • dry mouth
  • mild blood pressure elevation

Contraindications

  • recent myocardial infarction
  • unstable angina
  • left ventricular hypertrophy
  • significant arrhythmia
  • history of Stevens-Johnson syndrome
  • psychotic disorders
  • pregnancy
  • concurrent MAOI use

Interactions

  • hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
  • cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
  • warfarin: CYP2C9 inhibition raises INR(moderate)
  • phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
  • MAOIs: potential hypertensive reaction(major)
  • classical stimulants: additive cardiovascular and sleep-disruption effects(moderate)

Which Should You Take?

Alpha-Lipoic Acid comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Armodafinil is the right call when one of the conditionals below applies.

Edge case: If you want to avoid controlled substance, Alpha-Lipoic Acid is the more accessible choice.

Default choice: Alpha-Lipoic Acid. Lower friction to source, and broader goal coverage. Reach for Armodafinil only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Alpha-Lipoic Acid and Armodafinil?

Alpha-Lipoic Acid and Armodafinil differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Alpha-Lipoic Acid or Armodafinil?

Alpha-Lipoic Acid half-life is 0.5 hours; Armodafinil half-life is 15 hours.

Can you stack Alpha-Lipoic Acid with Armodafinil?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper